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ABSTRACT: Periodontitis is a bacterial inflammatory disease leading to attachment loss 
with the consequence of tooth loss. There exists a multifactorial risk pattern including bacte-
rial challenge, smoking, age, sex, diabetes, socio-economic and genetic factors. Smoking has 
the highest impact on the course of the disease modulated by all the other factors. Here, we 
report the relationship between smoking and the polymorphisms of genetic polymorphisms 
inflicted in the pathogenesis. 
In a randomly selected population-based study, 1083 subjects were typed for the 
polymorphisms of the IL-1 genotype, FcγRIIIb receptor gene, myeloperoxidase and N-
acetyltransferase (NAT2) and related to their periodontal state. Smoking behavior was as-
sessed including present and past quality and quantity of smoking. 
There is a significant dose-effect relationship between the exposure to tobacco smoke 
and the extent of periodontal disease assessed as attachment loss and tooth loss. Moreover, 
there are gene-environmental interactions as subjects bearing variant genotypes show an 
enhanced smoking-associated risk of the disease modulated by these genotypes. In non-
smokers, the impact of these genetic polymorphisms is mostly negligible. 
This study provides support for the hypothesis that subjects bearing genetic variants of 
polymorphically expressed phenotypes are at an increased risk of periodontitis when smok-
ing. Mostly, this may be accomplished via the influence of smoking-related impairment on
defense mechanisms rather than on the pathogenic pathways.  
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INTRODUCTION 
 
Periodontitis is a very common inflammatory dis-
ease caused by oral bacteria and leading to irreversible 
attachment loss, bone destruction and eventually to 
tooth loss. Approximately 30% of the adults in Europe 
are affected, among them 5-15% with severe perio-
dontal disease [1]. Similar figures were reported for the 
U.S.A. [2]. An interest in risk assessment for dental 
conditions came from the observation that some people 
are more likely to be affected by the sequelae of 
periodontitis than others [3]. Whereas the infection is a 
necessary prerequisite for the development of 
periodontitis, its course and severity depend on a 
number of inherited and environmental conditions. 
Thus, periodontal diseases present a wide range of 
clinical variability and severity. Both environmental 
and genetic factors contribute to individual variations in 
the etiology of periodontal diseases [4]. This individual 
susceptibility seems to be of major importance in deter-
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mining the manifestation and progression of the disease 
[5]. Now there exists evidence that the inter-individual 
variability in this condition depends on genetic factors, 
probably most of them as yet unidentified [6,7]. 
Smoking is one of the major environmental risk 
factors of periodontitis as shown in numerous studies 
(for reviews see [8,9]). In different studies, smoking 
was confirmed as a risk factor for periodontitis with 
odds ratios varying between 2.5 and 6 [10]. In sub-
groups of patients the risk may be even higher, 
especially in the younger. Smoking is not only a risk 
factor for the severity of the disease, but smoking also 
delays healing and is associated with refractory perio-
dontitis. Although the correlation between tobacco use 
and periodontal disease is quite strong, the role of 
tobacco in the pathogenesis of periodontal disease is 
uncertain. Environmental-gene interactions may play 
some role in the risk of the disease. Candidates for such 
genetic susceptibility factors are polymorphisms of 
genes modulating the immune response (e.g. FcγRIII 
receptors [11, 12]), genes inflicted in metabolism of 
products of tobacco smoke (Myeloperoxidase [13], N-
acetyltransferase [14]), genes in the process of inflam-
mation (interleukin-1 [15, 16]) or related to tissue 
destruction (metalloproteinases [17]).  
All these genes are expressed polymorphically, 
i.e. at least two different types of the gene product exist 
in a population in a high and constant proportion. 
Consequently, the proteins expressed by the wildtype or 
mutated genes function differently in the pathogenesis 
of diseases influenced by them. A schematic represen-
tation of the course of periodontitis including modifying 
risk factors is depicted in Fig. 1. N-acetyltransferase 
(NAT2) and myeloperoxidase (MPO) are enzymes 
participating in the metabolism of xenobiotics including 
arylamines from tobacco smoke. In addition, MPO is 
inflicted in defense against bacterial challenge and 
inflammatory tissue destruction. Interleukin (IL-1) 
proteins play a pivotal role in chronic inflammation and 
function as stimulators of matrix destruction and bone 
resorption leading to tooth loss. Leukocyte Fcγ 
receptors mediate the effects of immunoglobulins and 
the variant genotypes express phenotypes of diminished 
affinity for IgG. They are expressed on neutrophils, 
macrophages, monocytes etc, all of them cell types 
invading inflamed tissues as the periodontal gingiva. 
Numerous studies on the above mentioned and 
other genetic factors revealed risk-modulating effects 
for periodontal diseases. However, it is quite unclear if 
these effects alter the periodontal phenotype as such or 
if the action of other risk factors is modulated, affecting 
the periodontal outcome in an indirect way. As smoking 
is the most important risk factor for periodontitis, the 
objective of this study is to evaluate the interaction 
between smoking and various genetic factors known to 
have an impact on the course and severity of perio-
dontitis. In a population-based, cross-sectional study we 
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Fig. 2.  Illustration of separation criteria between perio-
dontally ‘diseased’ and ‘healthy’ subjects, indicated by
the shaded areas. Quantils to dichotomize the continuous 
variable % attachment loss into ‘cases’ (upper quantils) versus 
‘controls’ lower quantils. Numbers on the ordinate give the 
cut-offs as  attachment loss ≥ 4mm in percent of the sites 
measured. 
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Fig. 1. Periodontitis as multifactorial disease: development of 
periodontal disease from  bacterial challenge producing 
plaque to severe disease. Abbreviations: Fcγ: Fcγ-receptors; 
IL-1: polymorphisms of interleukin-1 clusters; MMP-1: met-
alloproteinase-1 (collagenase); MPO: myeloperoxidase; 
NAT2: N-acetyltransferase 2.  
 
performed genotyping for different polymorphisms and 
related them to the smoking behavior of the par-
ticipants. 
 
MATERIAL AND METHODS 
 
Subjects 
3148 subjects were randomly selected from a 
population of 210,000 inhabitants of the German part of 
Pomerania in a study designated as SHIP (Study of 
Health In Pomerania). The design of the study, 
recruiting of participants and the scope of this 
population-based cross-sectional health survey were 
outlined elsewhere [18]. In this group, the most 
profound smoking-related differences in periodontal 
parameters were recognized between the ages of 40-60. 
Therefore, all subjects in the age range of 40 – 60 years 
(N = 1103) were included in the study reported here. 
Characteristics of these subjects, relevant to the 
objective of the study, are displayed in Table 1. 
 
Clinical status 
The smoking status and habits of all subjects 
were assessed by an extensive questionnaire comprising 
31 items concerning present and past quality and 
quantity of smoking. The items included questions as to 
whether the subjects had ever used tobacco products, 
the age at which they started smoking (and, if ap-
plicable, ceased smoking) and the frequency and 
duration of smoking. The dose smoked was registered 
as ‘packyears’, i.e. the packs of cigarettes smoked daily 
multiplied by the years of reported smoking. Another 
approach distinguished between subjects who never 
smoked and former smokers from those who are current 
smokers. In this study smokers were classified as 
regularly smokers when smoking at least 1 cigarette/ 
day. The group of subjects designated as ‘ever smokers’ 
comprised current and former (quitted) smokers. In an 
independent study (n = 335), we proved by cotinine 
determinations that no more than 2-3 % of the subjects 
gave answers not consistent with their true smoking 
behavior. Investigations in representative population 
samples provided evidence that self-reported smoking 
status is accurate [19].The periodontal state was 
assessed by trained dentists. Assessment included 
probing depth, attachment loss, bleeding and plaque 
index. The periodontal examination was carried out on 
either the left or right quadrants and the examination 
side was changed from subject to subject. All fully 
erupted teeth were assessed excluding third molars. A 
maximum of 14 teeth per subject was examined. 
Attachment loss and probing depth were assessed with 
a periodontal probe (PCP 11, HuFriedy, Chicago IL.) at 
mesiobuccal, distobuccal, midbuccal and midlingual 
aspect on each selected tooth. The measurements were 
made in whole millimeters.  
 
Genotyping  
Genomic DNA was extracted from leukocytes 
isolated from venous blood. Of the 1103 subjects 
enrolled, 1085 were successfully genotyped for the 
variants of the IL-1 gene cluster. The remaining refused 
DNA analyses, or genotyping failed. Genotyping was 
performed at positions IL-1B +3954, IL-1B –511 and 
IL-1A -889 according to methods based on PCR and 
restriction enzyme digestion as described elsewhere 
[20]. Sequences of the primers employed were the same 
as described for IL-1A –889 in [21], IL-1B –511 and 
IL-1B +3954 in [20]. Restriction enzymes used were 
purchased from BioLabs (Schwalbach, Germany): Nco 
I (IL-1A –889), Ava I (IL-1B –511), Taq I (IL-1B 
+3954). By general agreement, subjects with at least 
one variant allele of each IL-1A and IL-1B were 
designated as ‘genotype positive’. This is the composite 
genotype suggested by Kornman et al. [20] to be a 
susceptibility factor for an enhanced periodontitis risk.  
Of the 1103 subjects enrolled, 1083 were 
successfully genotyped for MPO polymorphism. 
Genotyping for MPO G-463A was performed by 
PCR/RFLP according to the method described by 
Cascorbi et al. [22]. For PCR we used the primers 
forward 5’-CGG TAT AGG CAC ACA ATG GTG 
AG, reverse 5’-GCA ATG GTT CAA GCG ATT CTT 
C; the amplified PCR fragment was digested with 
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Fig. 3.  Proportion of smokers among subjects of increasing 
extent of periodontal disease as shown by quintiles according 
to Fig. 2. Black bars: current smokers only, gray bars: current 
and quitted smokers (ever) .  
 
endonuclease AciI in order to distinguish the genotypes 
wild-type –463 G/G, heterozygous G/A, and homo-
zygous A/A.  
The coding region DNA sequence of the NAT2 
gene was amplified by PCR, essentially as previously 
described [13]. Mutations at positions T341C, G590A, 
and G857A were detected by restriction fragment 
length differences (RFLP) or allele specific PCR as 
described. In order to predict the phenotype from 
genotyping, subjects bearing one or both alleles 
NAT2*4 (dominant wild-type) were considered as 
‘rapid‘ acetylators, those with two variant alleles as 
‘slow‘ acetylators [24]. As most NAT2 variants involve 
two or three point mutations, ‘homozygous’ refers to 
allele combinations rather than point mutations.  
The polymorphic sites of the FcγRIIIa, and - 
RIIIb genes were determined also by PCR method-
ology. The methods for genotyping were essentially as 
described; FcγRIIIa-158V/F [25] and FcγRIIIb-
NA1/NA2 [26], respectively. 
 
Statistics 
Periodontal disease occurs as a continuous range 
from minor signs to severe disease, complicated by the 
variability between different subjects and between the 
teeth within a particular individual. Thus, in order to 
avoid any arbitrarily chosen disease criteria or cut-offs, 
we used strictly statistical methods to distinguish 
periodontally ‘healthy’ from ‘diseased’ subjects. To 
differentiate the extent of attachment loss (percent of 
sites exceeding 4 mm) quantils (quartils or quintils) 
were calculated and subjects in the upper quantils of 
distribution (‘cases’) were compared with those in the 
lower ones with no or minor attachment loss 
(‘controls’). This method is explained in Fig. 2. Most 
severe cases of periodontitis were defined as subjects 
with an extent of attachment loss ≥ 6 mm in the 
uppermost decentil (more than 40 %). 
Logistic regression analyses were performed by 
STATVIEW (SAS Institute, Cary, NC). ANOVA and 
contingency table distributions were also used as well 
as the Kruskal-Wallis test for the comparison of 
differences occurring between three genotypes. 
 
RESULTS  
As shown in Table 1, smokers have more severe 
periodontitis and a higher extent of the disease 
compared to subjects who never smoked. This is not 
attributable to age, sex, education or diabetes – all other 
risk factors of periodontal diseases. Doubtless, the 
higher the extent of periodontal disease the higher the 
number of smokers is in the respective group of 
subjects. The ratio of smokers to non-smokers is 
steadily increasing from the group with no or slight 
signs of the disease (first quintil in Fig. 3) to that with a 
high extent of attachment loss (5th quintil). The 
smoking-associated risk for the upper quintil of 
measured attachment loss increased sevenfold as 
compared to the lowest quintil, i.e. the crude odds ratios 
were 6.88 (95% confidence interval 4.15 – 11.41, p < 
0.0001) and 4.51 (95% C.I. 2.98 – 6.82, p < 0.0001) for 
current and ever (i.e. present and quitted) smokers, 
respectively. 
In the Caucasian population studied here, the 
assessed gene frequencies including the 95% confi-
dence intervals were for NAT2 – slow acetylating 
phenotype 57.1 % (54.1 – 60.0), MPO low expression 
A/A – A/G genotypes 34.1 % (31.1 – 36.9), FcγRIIIa-
158F low IgG affinity 57.4 % (54.4 – 60.3), FcγRIIIb-
NA2 – low affinity 86.9 % (84.8 –88.8) and IL-1 – risk 
(positive) genotype 36.4 % (33.6 – 39.3). These 
frequencies are in agreement with other studies made in 
Caucasian populations. 
From an epidemiological point of view, considering the 
frequencies of smoking and the putative genetic factors 
as well as the prevalence of periodontitis, an interaction 
between these factors seems reasonable. In the 
following, it will be shown that each of these genetic 
polymorphisms has an impact on the extent of 
periodontal disease and that it is mediated by the inter-
action with smoking.  
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Fig. 4. Percent attachment loss ≥ 4mm among smokers (filled 
circles) and non-smokers (open circles) separated according 
to their Fcγ-RIIIb genotypes NA1/NA1, NA1/NA2 or 
NA/2NA2. Kruskal-Wallis test results in p = 0.024 and p = 
0.797 for smokers and non-smokers, respectively.  
Table 1. Subjects enrolled in the Study of Health in Pomerania (SHIP) and assessed for periodontitis and their smoking state. 
Shown: the numbers of subjects, ratios, or the median and range of parameters where appropriate. 
  Never smoked  Ever smoked  Current smokers 
Number of subjects  559  544  298 
Female / male  388 / 171  206 / 338  164 / 134 
Age, mean ± SD (range 40 - 60)  51.3 ± 5.7  49.7 ± 5.8  48.8 ± 5.7 
Number of teeth, median *  22  21  19 
% Attachment loss ≥ 3 mm, median  48.2 68.7  75.0 
% Attachment loss ≥ 4 mm, median  18.8 34.0  47.5 
% Attachment loss ≥ 6 mm, median  0 5.0 8.0 
% Probing depth ≥ 4 mm  6.1 12.5  17.9 
Probing depth, mean mm  2.5 ± 0.7  2.8 ± 0.8  2.9 ± 0.8 
Diabetes  28 (5.0 %)  38 (7.0 %)  15 (5.0 %) 
High School = yes  101 (18.1 %)  87 (16.0 %)  40 (13.4 %) 
*except 3
rd molars       
Leukocyte Fcγ receptors mediate the effects of 
immunoglobulins induced for defense against perio-
dontopathogenic bacteria. Whereas in this study no 
effect was seen with the different FcγRIIIa types, the 
FcγRIIIb influence the disease parameters. In Fig. 4, the 
different genotypes show no differences in non-
smokers. However, smokers show a significantly in-
creased attachment loss when heterozygous or homo-
zygous for the variant low affinity allele FcγRIIIb-NA2.  
Likewise, subjects bearing the ‘risky’ genotype of 
interleukin-1 (at least one variant allele of each IL-1A 
and IL-1B) belong to the group with an enhanced 
attachment loss only when smoking. Non-smokers do 
not differ in their periodontal parameters irrespective of 
the IL-1 genotype. This is illustrated by the results of 
logistic regression analyses as shown in Fig. 5a. 
Attachment loss is dependent on the age of the test 
persons. The probability of disease increases con-
siderably for smokers and, beyond this, in smokers who 
are genotype-positive for the IL-1 polymorphism. 
Moreover, an exposure-effect relation can be demon-
strated in this gene-environmental interaction. Attach-
ment loss is an indicative symptom of periodontal 
disease, but tooth loss is the final result. Even though 
tooth loss is a highly variable parameter due to different 
fates of particular teeth (caries, dentists decisions, acci-
dents), the gene-dose effect is shown with the number 
of teeth remaining (Fig. 5b). Again, an increasing 
exposure to tobacco smoke is associated with increa-
sing effects indicated by the diminished number of 
remaining teeth. The tooth loss is reinforced in subjects 
bearing the IL-1 positive genotype. There are no differ-
ences in the mean ages, so the higher figures of pack-
years are not biased by higher age.  
Polymorphic variants of both N-acetyltransferase 
(NAT2) and myeloperoxidase (MPO) affect the extent 
of the periodontal state, especially attachment loss. 
Subjects designated as so-called ‘rapid acetylators’ 
(bearing at least one wild-type allele NAT2*4) or 
bearing the highly expressed MPO variant (homo-
zygous –463 G/G) are at an increased risk of 
periodontitis when smoking. However, as non-smokers 
the rapid acetylating NAT2 genotypes are at a lower 
risk. This is in contrast to MPO with a lower risk in 
subjects bearing the low expression variants A/G or 
A/A. This is shown in Table 2 by the frequency 
distribution of the most severe periodontitis cases 
exhibiting more than 6 mm attachment loss.  
 
DISCUSSION 
 
To date, the complex interaction of environmental 
factors with periodontal diseases is poorly understood. 
Although the correlation between tobacco use and 
periodontal disease is quite strong, the role of tobacco 
in the pathways of periodontal disease is uncertain [27]. 
In addition, there is obviously an interaction between 
hereditary factors and smoking, the latter being also  
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Table 2. Impact of gene polymorphisms of enzymes participating in the metabolism of tobacco smoke products: N-
acteyltransferase 2 (NAT2) and myeloperoxidase (MPO). Shown is the distribution of subjects with severe periodontitis (more 
than 30% of sites have attachment loss > 6mm) versus those having no attachment loss ≥ 6mm. NAT2 high activity: homo- or 
heterozygous with allele NAT2*4; MPO highly expressed variant coded by homozygous G/G subjects. Shown are crude odds 
ratios (95 % confidence intervals, C.I.). 
    NAT2    MPO  
Smoking High  activ-
ity variant  
AV6mm > 
30% 
AV6mm = 0  odds ratio  AV6mm > 
30% 
AV6mm = 0  odds ratio 
never  present  22  132  1.0 (ref.)  38  160  1.0 (ref.) 
never  no  29  128  1.4 (0.7 – 2.6)  13  100  0.5 (0.3 – 1.1)  
current  no  38  54  4.2 (2.2 – 8.2)  21  67  2.9 (1.5 – 6.0) 
current  present  28  24  7.0 (3.3 – 15.2) 45  114  4.0 (2.2 – 7.0) 
              
associated with sex, age, education, stress and other risk 
factors of periodontitis. 
With respect to smoking, direct local effects are 
to be distinguished from systemic effects. Complex 
interactions between circulatory and immunological 
effects exerted by nicotine as well as toxic effects by 
arylamines and other products of tobacco smoke are to 
be taken into consideration. Thus, it seems plausible to 
study genetic dispositions of inflammation-related 
factors as well as toxicity-modulating metabolic poly-
morphisms.  
As can be concluded from the results presented, 
smoking is the most important risk factor: it increases 
the risk of periodontitis irrespective of the genotype. 
This risk is further aggravated in subjects bearing 
particular alleles of the polymorpically expressed genes 
studied. The risk of the disease may be worsened by 
either the genetic or the environmental agent, possibly 
the genotype increases the effect of the agent [28]. 
Smoking periodontitis subjects typically failed to 
respond to specific microbes [29]. Arylamines when 
detoxified insufficiently act as immunosuppressants 
[30], they are activated to reactive intermediates in 
leukocytes or by activated neutrophils and monocytes. 
The binding of IgG immune complexes by 
phagocytes is an important defense mechanism of 
inflammation. The activation of the FcγRIII receptors 
mediates the release of cytokines, phagocytosis and 
cell-mediated cytotoxicity [31]. The polymorphism of 
FcγRIIIb influences the ability of neutrophils to 
phagocytize IgG-opsonized particles. The finding of an 
association between the frequency of the FcγRIIIb 
allele of low IgG affinity and the extent of periodontitis 
is in agreement with studies by Kobayashi et al. [12]. 
This receptor isoform exhibits a lower affinity toward 
IgG1 and IgG3. As shown (Fig. 4), smoking and the 
presence of the FcγRIIIb NA2 allele leads to an in-
creased attachment loss indicating more severe disease. 
This is in agreement with results showing that 
smoking lowered the sensitivity to the stimulation of Fcγ 
receptors [32]. Ligation of FcγR causes the release of 
inflammatory mediators, among them interleukin IL-1. 
Phenotypic differences exist in interleukin levels 
corresponding to the genotype and these differences are 
related to periodontal disease [33]. The positive IL-1 
genotype results in enhanced levels of pro-inflammatory 
cytokines and an increased formation of interleukins is 
known to be induced by nicotine and/or bacterial 
lipopolysaccharides [34, 35]. These changes may serve 
as predisposing factors in periodontal disease. IL-1 
gene polymorphisms are highly related to plasma levels 
of CRP and fibrinogen which are markers of systemic 
inflammation [36]. Frequently, such signs of systemic 
inflammation are enhanced in smokers. Different 
studies revealed the suppression of cytokine production 
by tobacco smoke extracts [37]. Release of cytokines 
from neutrophils seems to be affected more by smoking 
than the disease. 
However, in gingival crevice fluid no difference 
was found in IL-1ß concentrations [38]. 
It is well known that myeloperoxidase activity is 
increased in inflammatory gingival tissue. Inflam-
mation- related recruitment of neutrophil leukocytes 
into the affected tissue is most likely responsible for 
the action of MPO in the gingiva. Exchange of an 
adenosine for a guanosine at position – 463 in the 5’-
untranslated region of the MPO gene leads to the loss of 
a transcription factor binding site. Reduced binding of 
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transcription factor SP1 results in a diminished 
expression of MPO. Smoking may override this 
protection of diminished enzyme activity in the most 
affected individuals (more than 30% attachment loss ≥ 
6 mm, Table 2). However, in subjects with more 
moderate disease, the protective effect is still detectable 
in smokers also [13]. Possible protective effects seen 
in non-smokers bearing at least one A allele of MPO 
are not obvious in smokers. Probably, the MPO 
polymorphism-related effects are sex-specific as the 
protective role of the –463A allele was detected in 
women but not in male subjects [13]. 
Smoking subjects who were phenotypically rapid 
acetylators had more severe signs of periodontal disease 
than non-smoking patients regardless if phenotypically 
rapid or phenotypically slow. As shown, only subjects 
bearing both risk factors – smoking and metabolic rapid 
phenotype – are prone to increased attachment loss. 
These data suggest that the increase in risk imposed by 
NAT2 acetylation may be related to smoking. Again, 
this influence was obvious only in the most affected 
individuals. In a former study, we have shown that, in 
contrast, smoking slow acetylators bear a higher risk 
when bone loss was the parameter assessed to 
characterize the disease [14]. Any explanation of the 
association between the acetylation polymorphism and 
the immune/inflammatory responses remains specu-
lative at this time. The known role of the enzyme NAT2 
is related to the detoxification of foreign substances in 
the liver. Nicotine induces a local vasoconstriction 
reducing blood flow and gingival bleeding. On a 
systemic level, smoking leads to diminished levels of 
circulating IgG2, the immunoglobulin reactive with 
periodontitis-associated bacteria [29]. Systemic altera-
tions in the host response by genetic variations in the 
N-acetyltransferase metabolic capacity for arylamines 
may explain the mechanism for the results shown here. 
Possibly, the impaired metabolism of smoke-derived 
arylamines may have relations to other known risk 
factors, for instance the IgG2-related immune reactions. 
Arylamines may act as immunosuppressants [30]. They 
are activated to reactive intermediates in leukocytes by 
NAT [39], by activated neutrophils and monocytes 
releasing myeloperoxidase or even by tissue-specific 
activation by prostaglandin H synthase [40]. 
In conclusion, neutrophils are the most probable 
effector cells of the smoking-related effects associated 
with the genetic polymorphism shown. Recruitment of 
neutrophils and their exaggerated responses are a critical 
component in the pathogenesis of periodontal disease 
including local tissue injury [41]. Their function is im-
paired in smokers with chronic periodontitis [42]. The 
polymorphisms related to this central role represent 
major steps in this interplay as cell recruitment by IL-1, 
cell activation by IgG binding at Fcγ receptors or release 
of myeloperoxidase from the cellular granules. Impair-
ment of these functions by different phenotypes seems to 
have only minor effects on the disease. The additional 
harmful tobacco smoke may override the potential for 
compensation. The extent of such interplay may depend 
on quantitative dose-effect relationships. A recent study 
suggests dose-effect relationships exist with respect to 
the genetic as well as the environmental factor [43]. 
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